First Tracks Biotherapeutics Inc. (TRAX)
NASDAQ: TRAXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
TRAX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.75B
- EPS (TTM)
- -$4.71
- Dividend yield
- None
- 52-week range
- 14.72 – 54.78
- Day range
- 41.51 – 44.51
- Volume / Avg
- 504.36K / 826.70K
- Beta
- —
- Shares outstanding
- 42.02M
52-week range
TRAX stock today
On Nov 20, TRAX ended the session at $41.64, shedding $2.82 (6.34%), versus the S&P 500's 3.70% decline. Shares are 24.0% below their 52-week high of $54.78, set on Nov 10, 2026 and 182.9% above the 52-week low of $14.72, in the middle of the past year's range. First Tracks Biotherapeutics has posted a net loss over the last twelve months (EPS of -$4.71), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About First Tracks Biotherapeutics
Company profileFirst Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States. Its products includes ANB033, a novel anti-CD122 antagonist that targets the shared beta subunit of the IL-15 and IL-2 receptors; Rosnilimab, a antibody engineered to selectively deplete pathogenic T cells in both the periphery and inflamed tissues; and ANB101, a BDCA2-modulating antibody designed to specifically target plasmacytoid dendritic cells (pDCs).
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Daniel R. Faga
- Headquarters
- San Diego, CA
- Employees
- 104
- Website
- firsttracksbio.com
Analyst forecast
ForecastConsensus (12 analysts)
strong_buy
Avg. price target
$75.17+80.52%
- Strong buy 3
- Buy 9
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 11, 2026
- EPS actual vs est.
- $-0.88 vs $-0.92
- Surprise
- +4.35%
TRAX news
All TRAX news- First Tracks Biotherapeutics Q3 Loss Narrows As ANB033 Programs AdvanceNasdaqTRAX, WSO.B
- First Tracks Biotherapeutics, Inc. GAAP EPS of -$0.88 beats by $0.03Seeking Alpha
- First Tracks Biotherapeutics Announces Participation in Upcoming Investor ConferencesGlobeNewswire
- First Tracks Biotherapeutics Reports Third Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswire
- First Tracks Biotherapeutics announces $200M private placementSeeking Alpha
- Stocks Settle Lower as Crude Prices Jump and Chipmakers FallNasdaqALK, UAL, SNDK, CVX
- Stocks Pressured by Rising Crude Prices and Chipmaker WeaknessNasdaqAMAT, AVGO, SNDK, INTU
- Stocks Mixed Ahead of Q3 Earnings SeasonNasdaqMPC, SNDK, ADI, SLB
First Tracks Biotherapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| STOKStoke Therapeutics Inc. | 26.81 | -0.45% | $1.75B | vs TRAX |
| ETONEton Pharmaceuticals Inc. | 60.85 | -0.83% | $1.76B | vs TRAX |
| SDGRSchrodinger Inc. | 22.93 | -12.95% | $1.72B | vs TRAX |
| KRSAKorsana Biosciences Inc. | 37.56 | +5.95% | $1.71B | vs TRAX |
| ZYMEZymeworks Inc. | 26.14 | -2.68% | $1.81B | vs TRAX |
| MRVIMaravai LifeSciences Holdings Inc. Class A | 6.98 | -2.92% | $1.81B | vs TRAX |
| RAREUltragenyx Pharmaceutical Inc. | 16.48 | -4.30% | $1.68B | vs TRAX |
| BRVEBraveheart Bio Inc. | 20.39 | +5.81% | $1.67B | vs TRAX |
Indexes, lists and sector
First Tracks Biotherapeutics stock FAQ
What is First Tracks Biotherapeutics's stock price today?
TRAX last traded at $41.64 as of Nov 20, 4:00 PM EST, down 6.34% on the day. Prices are delayed at least 15 minutes.
Who is First Tracks Biotherapeutics's CEO?
Mr. Daniel R. Faga is the chief executive officer of First Tracks Biotherapeutics Inc., which has about 104 employees.
What is the TRAX 52-week high?
The 52-week high for TRAX is $54.78 and the 52-week low is $14.72. The stock is currently 24.0% below its high.